Elastin Biosciences Ltd

Elastin Biosciences is a London-based biopharma company focused on the development of small molecule therapies to treat diseases and conditions linked to the loss of elastin. Elastin has pioneered a combination approach using small molecules to recover elastin deposition and inhibit its degradation. Elastin is a vital protein in the human body that imparts elasticity and resilience to various tissues, such as the skin, lungs, and blood vessels. Elastin degrades over time due to aging, leading to a loss of tissue elasticity and function, which is associated with numerous age-related diseases. The Company’s Elastin Restoration Platform leverages a combination of proprietary small molecules designed to fortify the structural integrity of crucial tissues, including those in the cardiovascular and epidermal systems, by inhibiting elastin degradation and increasing elastin production. Elastin’s lead development program, currently completing in vivo proof-of-concept, has demonstrated an ability to increase elastin expression and arterial tensile strength in models of abdominal aortic aneurism and Williams syndrome, a rare a multisystem disorder characterized by elastin arteriopathy, most often manifesting as supravalvuar aortic stenosis. London-based Elastin Biosciences emerged from Longaevus Technologies in June 2023.